Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT00181649
Other study ID # 2003P001209-2
Secondary ID
Status Withdrawn
Phase Phase 2
First received September 9, 2005
Last updated May 8, 2013
Start date September 2006
Est. completion date May 2011

Study information

Verified date May 2013
Source Massachusetts General Hospital
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The purpose of the study is to assess the safety and determine the effects of the hormone prolactin on lactation (breast milk production).


Description:

Subjects will participate in a randomized, double-blind, placebo-controlled, crossover trial comparing breast pumping, alone, to breast pumping and r-hPRL. Subjects will have one week of instruction with the breast pump alone. Subsequently, subjects will receive 2 weeks of r-hPRL or placebo followed by 2 weeks of the alternate treatment.

Week 1: Study day 1, a baseline prolactin level will be obtained and subjects will be taught to use an electrical, hospital grade breast pump by a designated lactation consultant. Subjects will pump for 10 minutes at each breast. The total volume of milk will be recorded in a diary throughout the study. Prolactin levels will be obtained every 10 minutes for 60 minutes after pumping begins, then every 30 minutes for a total of 3 hours. Subjects will pump 3 times per day increasing to 8 times per day by the end of the first week and will continue this regimen throughout the study.

Week 2: One week after the initial visit, subjects will return to the GCRC for re-evaluation of the pumping technique and the first dose of medication. Subjects will pump for 10 minutes at each breast as on day 1 and prolactin levels will be obtained every 10 minutes for 60 minutes, then every 30 minutes for a total of 3 hours. At 3 hours, r-hPRL 60 mg/kg or placebo will be administered SC. Blood will be drawn every 10 minutes for 60 minutes, every 30 minutes for 2 hours, then at 4, 6 and 8 hours to obtain a peak prolactin level. Vital signs will be monitored every 15 minutes for the first hour, then every 2 hours for a total of 8 hours. Subjects will pump both breasts every 3 hours, starting after the r-hPRL or placebo injection. Subjects will be taught to give themselves SC injections and will administer their second dose of SC r-hPRL or placebo 12 hours after the first dose. Subjects will continue SC r-hPRL or placebo administration every 12 hours for the next 14 days. They will continue to pump daily, approximately every 3 hours, with a 5 hour break in the night to sleep. Subjects will be asked to refrigerate all milk and bring it in to GCRC visits for prolactin levels.

Subjects will return weekly for 4 additional visits (weeks 3, 4, 5, 6). At the weekly visits, blood will be drawn at baseline for a prolactin level and r-hPRL or placebo will be administered. Blood will then be drawn every 10 minutes for 60 minutes, then every 30 minutes for 2 hours, then every 2 hours for a total of 8 hours after the injection. Vital signs will be monitored as described above. At the week 4 visit, subjects will be switched to the alternate treatment for weeks 4 and 5. Subjects will be seen 14 days after their final injection. A baseline prolactin level will be drawn, then milk will be pumped, as previously. Blood will be drawn every 10 minutes for 60 minutes, then every 30 minutes for a total of 3 hours. A 1 cc sample of the milk will also be obtained 14 days after the final injection for analysis of composition. All side effects of r-hPRL will be recorded throughout the study. All milk obtained during the study will be stored and the milk composition will be determined before it is used. Infants receiving milk produced during the study will initially be monitored in the GCRC under the supervision of a neonatologist.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date May 2011
Est. primary completion date May 2011
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria:

- Healthy, non-postpartum women, aged 18-45 years, who desire to lactate for their adoptive children

- Normal thyroid-stimulating hormone (TSH) and prolactin level

- Normal adrenal gland function or taking physiological glucocorticoid replacement

- No medical illnesses that contraindicate breastfeeding

- HIV negative

- Normal breast development

Exclusion Criteria:

- Use of medications known to increase prolactin

- Anatomical breast abnormalities

- Previous mammoplasty or breast augmentation

- Current use of hormonal contraception

- Allergies to mannitol

- Medications contraindicated for breastfeeding mothers

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Recombinant human prolactin


Locations

Country Name City State
United States Massachusetts General Hospital Boston Massachusetts

Sponsors (1)

Lead Sponsor Collaborator
Massachusetts General Hospital

Country where clinical trial is conducted

United States, 

References & Publications (2)

Powe CE, Allen M, Puopolo KM, Merewood A, Worden S, Johnson LC, Fleischman A, Welt CK. Recombinant human prolactin for the treatment of lactation insufficiency. Clin Endocrinol (Oxf). 2010 Nov;73(5):645-53. doi: 10.1111/j.1365-2265.2010.03850.x. — View Citation

Powe CE, Puopolo KM, Newburg DS, Lönnerdal B, Chen C, Allen M, Merewood A, Worden S, Welt CK. Effects of recombinant human prolactin on breast milk composition. Pediatrics. 2011 Feb;127(2):e359-66. doi: 10.1542/peds.2010-1627. Epub 2011 Jan 24. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Breast milk production 28 days No
Secondary Breast milk volume 28 days No
Secondary Breast milk prolactin levels and content 28 days No
See also
  Status Clinical Trial Phase
Completed NCT02542527 - Evaluation of the Functionality of a Fluid Filled Single Breast Pump N/A
Terminated NCT02755194 - "Drugs in Lactation" Analysis Consortium
Terminated NCT00851591 - Effect of Fenugreek on Milk Production N/A
Completed NCT00181610 - Recombinant Human Prolactin for Lactation Induction Phase 2
Completed NCT04024865 - Domperidone and Risk of Serious Cardiac Events in Postpartum Women
Terminated NCT02378233 - Iodine Status in Swedish Lactating Women - Effect of Iodine Supplementation in the Thyroid Function of Mother and Infant N/A
Recruiting NCT06203444 - An Open-label Study to Evaluate the Pharmacokinetics of Oral Tenapanor in Breast Milk of Lactating Females Phase 1
Completed NCT01747668 - Lactation Fortification Study Phase 3
Completed NCT01463202 - Timing of Postpartum Depot Medroxyprogesterone Acetate Administration on Breastfeeding, Contraceptive Continuation, and Depression Phase 4
Completed NCT02621827 - Vitamin D Half-life in Pregnancy and Lactation N/A
Terminated NCT04146909 - The Effect of Lactation on Insulin Sensitivity and Lipolysis in Women N/A
Completed NCT04593719 - Effect of Lactation Management Model on Breastfeeding Process N/A
Completed NCT01548313 - The Role of Human Milk in Development of Breast Fed Child's Intestinal Microbiota
Completed NCT02690675 - Iron Supplement Effect on Child Development N/A
Completed NCT05123183 - Nonpharmacological Methods and Lactation N/A
Completed NCT03091985 - Influence of the Brownie Breast Shield on the Dynamics of Milk Removal N/A
Completed NCT02190448 - Randomized, Placebo-Controlled Study of an Herbal Tea to Support Lactation N/A
Not yet recruiting NCT06264349 - Women and Maternity: Development of a Nutritional Education Project N/A
Recruiting NCT02384655 - Effect of Fenugreek Use in Mothers of Preterm on Breast Milk Production and Macronutrient Content Phase 1/Phase 2
Completed NCT02662517 - Growth Hormones and Cells in Human Milk Depending on Gestational Age